Cannabis sativa-derived compounds for beta cell health and diabetes prevention
Plant-derived molecules from Cannabis sativa extracts that reduce inflammation, inhibit inflammasome activation, and protect insulin-producing beta cells. Validated in cell models with two identified active single-molecule ingredients, advancing toward in vivo diabetes prevention studies.
Overview
This research program identifies and characterizes specific molecules derived from Cannabis sativa extracts that improve the health and survival of pancreatic beta cells—the insulin-producing cells whose dysfunction drives diabetes. The approach targets inflammation-driven beta cell loss, a key pathway in both type 1 and type 2 diabetes. By screening over 400 extracts, the team identified the top candidates and isolated two single-molecule ingredients that replicate the protective effects of whole extracts. The work addresses a significant unmet need in metabolic disease by offering a plant-based strategy to preserve beta cell function, potentially delaying or preventing diabetes onset.
Technical specifications
Mechanism of action:
- Modulates cannabinoid receptor 1 (CB1R) expression, which is implicated in obesity, insulin resistance, and beta cell dysfunction
- Reduces inflammation by downregulating NFkB phosphorylation, the first phase of Nlrp3 inflammasome activation
- Decreases anandamide production in macrophages challenged with high glucose and lipid conditions
Validation achieved to date:
- Screened over 400 Cannabis sativa extracts in cell, tissue, and animal inflammation models
- Tested top 10 candidates in the INS-1 beta cell viability model under high glucose/high lipid stress
- Confirmed top 2 extracts inhibit beta cell loss and inflammasome activation
- Identified two single-molecule ingredients with activity comparable to whole extracts
Planned next-stage validation:
- Testing in INS-1832/13 cells engineered for strong glucose-stimulated insulin secretion (GSIS), expressing both rat and human insulin
- In vivo studies in C57BLKS/J-leprdb/leprdb diabetic mouse model with pre-treatment (6 weeks) and post-treatment (3 months) protocols
- Blood biochemistry, tissue histology, and molecular profiling to assess diabetes prevention and symptom alleviation
Technology readiness level
The technology is at an early-to-mid stage of preclinical development. Active compounds have been identified through extract screening and validated in established beta cell and macrophage cell models. Two single-molecule ingredients have been isolated that match the efficacy of whole extracts. The program is advancing toward in vivo validation in a well-characterized diabetic mouse model, which represents a critical step before any potential therapeutic development or partnership for further translational work.
About University of Lethbridge
The University of Lethbridge is a mid‑sized public comprehensive research university based in Lethbridge, Alberta, with an additional campus in Calgary. Science Commons concentrates shared core facilities—such as the Central Analytical Facility and Microscopy—available to external partners on a fee‑for‑use basis, enabling co‑located, instrument‑rich collaboration. A well‑established co‑operative education program connects employers with student talent through structured work terms. The university sits within southern Alberta’s agri‑food ecosystem, near one of Agriculture and Agri‑Food Canada’s largest research centres in Lethbridge, supporting applied partnerships. Research is backed by Canada’s Tri‑agency and the Canada Foundation for Innovation, with technology transfer supported by a University‑Industry Liaison Office.
delivered to your inbox.